Scancell Holdings plc, ("Scancell" or the "Company") the developer of novel immunotherapies for the treatment of cancer , announces results for the year ended 30 April 2013.
Highlights during the period:
- Successful completion of Part 1 of the SCIB1 Phase 1/2 clinical trial
- Part 2 of the SCIB1 Phase 1/2 clinical trial fully recruited and on track for completion by the end of 2013
- Additional 8mg dose study underway, also expected to be completed by the end of 2013
- Development of new Moditope™ platform
- Strengthened IP with patents awarded in the US and Japan for protein Immunobody® technology platform
- Peter Allen appointed as a Director
Post period highlights:
- Placing and Open offer up to £6.5 million (announced today)
Richard Goodfellow, Joint CEO of Scancell, said:
“We have made excellent progress this year with the successful completion of Part 1 of our Phase 1/2 clinical trial for SCIB1, Part 2 remains on track and our additional 8mg dose study has also commenced. We are delighted that four of the six patients from the 2mg and 4mg dose groups are still alive with one patient remaining disease free two years after initiating treatment.
“We believe our innovative Moditope™ platform has the potential to generate a new class of powerful cancer immunotherapy treatments. We are putting funding in place to identify a lead from this programme and develop it through to the point at which we have secured regulatory approval to start clinical trials, a key value inflexion point. We are confident that such targeted further development of the Immunobody® and Moditope™ platforms will both strengthen Scancell's position as a leading immunotherapy player and allow it to realise an enhanced value for shareholders.”
Click here to read the full news article
For Further Information:
Scancell Holdings Plc + 44 (0) 74 2323 0 497
Dr Richard Goodfellow, Joint CEO
Professor Lindy Durrant, Joint CEO
Cenkos Securities +44 (0) 20 7397 8900
Camilla Hume
Stephen Keys
FTI Consulting +44 (0) 20 7831 3113
Simon Conway
Mo Noonan